Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine

Éloit, Marc; Gilardi-Hebenstreit, Pascale; Toma, B.; Perricaudet, Michel

doi:10.1099/0022-1317-71-10-2425

Cited by 83 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Construction of pMLP-gD or Ad-gD has been described previously (Eloit et al, 1990). These constructs harbour the same transcription unit, in which the gD gene of PRV strain NIA3 was placed under the control of the major late promoter of adenovirus type 2 followed by its tripartite leader sequence.…”

Section: Methodsmentioning

confidence: 99%

“…gD is a major immunogen of PRV (Wathen & Wathen, 1984 ;Eloit et al, 1988 ;Coe & Mengeling, 1990). Vaccination of mice or pigs with purified or recombinant gD, or recombinant virus vectors, conferred protection to the animals (Eloit et al, 1990 ;Ganne et al, 1994 ;Ishii et al, 1988 ;Marchioli et al, 1987 ;Riviere et al, 1992). We compared the efficiency of replication-defective adenoviruses and genetic immunization in the priming of neonate piglets born to immune sows against gD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth.

Monteil

Potier²,

Cariolet³

et al. 1997

Journal of General Virology

View full text Add to dashboard Cite

One of the main limitations of the vaccination of neonates from vaccinated or infected mothers is the interference by inherited maternal antibodies, which are known to inhibit the immune response against both live and inactivated vaccines. The efficiency of bypassing this inhibition by the transfer of an immunogenic glycoprotein gene, the gD gene of pseudorabies virus (PRV), into neonates was explored. The experiments were conducted in 1-day-old piglets, which are immunocompetent at birth. The same transcription unit (gD of PRV under the control of the adenovirus major late promoter) was delivered intramuscularly at birth either in the form of naked DNA or cloned in the genome of a replication-defective adenovirus. A booster injection of a conventional live PRV vaccine strain was

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth.

Monteil

Potier²,

Cariolet³

et al. 1997

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…Two prototypic viruses, adenovirus serotypes 2 and 5, have been the most extensively characterized biochemically and genetically and, thus, have been widely used in gene therapy and recombinant vaccination trials. [11][12][13][14][15] While these viruses have demonstrated the ability to be potent vectors with promising futures, data concerning their efficiency in transferring genetic material into intestinal epithelial cells are quite limited and somewhat speculative. [16][17][18][19] We have also experienced similar difficulties as in vivo and in vitro transduction studies suggest that, as enterocytes differentiate, Ad 5 transduction efficiency significantly decreases.…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo asessment of adenovirus 41 as a vector for gene delivery to the intestine

et al. 1998

View full text Add to dashboard Cite

In order to identify suitable adenoviral vectors for efficient tiated enterocytes, probable targets for oral gene delivery delivery of transgenic proteins and peptides to the intesbut rather resistant to adenovirus-mediated gene transfer, tine, the ability of adenovirus types 5 and 41 (an enter-28.4% of the population internalized the Ad 5 vector and otropic serotype) to bind to and enter undifferentiated and less than 10% bound the virus. Adenovirus 41 was differentiated enterocytes was assessed. FACS analysis efficiently internalized in differentiated enterocytes as showed no significant difference between the virions in 89.6% of the cellular population took up the virus while their ability to bind to undifferentiated Caco-2 cells as 37.4% bound the virus. These results were consistent with 81.6% of the cellular population bound adenovirus 5 (Ad 5) those observed in vivo in rat jejunum. Thus, molecularly and 79.8% bound Ad 41. Both virions were also efficiently engineered Ad 41-based recombinants could be highly internalized in this cell type as 99.6% of the cells took up efficient vectors for delivery of transgenic proteins to differAd 5, while 95.9% took up Ad 41. In studies with differenentiated enterocytes.

show abstract

“…Such replication-incompetent adenovirus vectors are currently being studied as attractive candidates mainly for gene therapy purposes. Immunization of experimental animals with the recombinant adenovirus containing genes in the E1 region can induce a systemic immune response to the foreign gene product even in the absence of viral replication and provide a protection against subsequent challenge [1,22,28,71,92,128]. Despite the safety advantages of replication incompetent viruses, the drawback of using such mutants is that high titers of virus must be injected into animals to elicit a strong immune response.…”

Section: Recombinant Adenovirusesmentioning

confidence: 99%

“…2) Viral DNA is maintained mainly as an episome for several months, the transduced gene being expressed during this time in such a way that a long lasting immune response can be expected. 3) All mammal species which have been tested to date, including chimpanzee, tamarin, cattle, pig, dog, ferret, rabbit, mice, hamster, and rat, develop an immune response against foreign genes carried by recombinant adenoviruses [1,10,16,22,39,60,71,75,89,90,114,115,134].…”

Section: Recombinant Adenovirusesmentioning

confidence: 99%

Recombinant Viral Vector Vaccines for the Veterinary Use.

Yokoyama

Maeda

Mikami

1997

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Recently, genetically engineering using recombinant DNA techniques has been applied to design new viral vaccines in order to reduce some problems which present viral vaccines have. Up to now, many viruses have been investigated for development of recombinant attenuated vaccines or live viral vectors for delivery of foreign immunogenic antigens. In this review, we introduced three kind of viruses; herpesviruses, vaccinia viruses, and adenoviruses, which have best widely been studied as recombinant vaccines or delivery vaccines for the veterinary use. -KEY WORDS: recombinant polyvalent vaccine, recombinant vaccine, viral vector.

show abstract

Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine

Cited by 83 publications

References 24 publications

Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth.

Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth.

In vitro and in vivo asessment of adenovirus 41 as a vector for gene delivery to the intestine

Recombinant Viral Vector Vaccines for the Veterinary Use.

Contact Info

Product

Resources

About